The company Cell Vault offers to hold consumers’ T cells for later use, but scientists suggest the service would benefit very few users.

About a quarter of lymphoma patients eligible for the cancer treatments are opting for experimental—and free—options instead.

Comparing the cells of cancer patients who did and did not respond to the immunotherapy could reveal biomarkers to predict who should receive it in the first place.

An early-stage clinical study finds that none of the 25 patients treated developed neurotoxicity or cytokine release syndrome, common hazards of the cancer immunotherapy.

The technology has wowed the field by all but obliterating some patients’ blood cancers, but solid malignancies present new challenges.

Tumor accessibility, heterogeneity, and microenvironment vary between the two classes of malignancies.

T cells modified to target disease-contributing B cells improved survival in two mouse models of the autoimmune disease.

The manuscript had amassed more than 50 comments about problematic figures and data on PubPeer.

The deal between the two biopharmaceutical giants will boost the purchaser’s cancer drug portfolio.